Canada markets closed

HAVN Life Sciences Inc. (HAVLF)

Other OTC - Other OTC Delayed Price. Currency in USD
Add to watchlist
0.1844+0.0055 (+3.09%)
At close: 03:04PM EST

HAVN Life Sciences Inc.

22071 Fraserwood Way
Unit 100
Richmond, BC V6W 1J5
Canada

http://www.havnlife.com

Sector(s)Healthcare
IndustryBiotechnology
Full Time Employees

Key Executives

NameTitlePayExercisedYear Born
Mr. Tim MooreCEO & Director136.19kN/A1959
Mr. Gordon Clissold FCGA, FCPAChief Financial OfficerN/AN/AN/A
Ms. Jenna PozarChief Operating OfficerN/AN/AN/A
Mr. Gary Joseph LeongChief Science OfficerN/AN/A1965
Dr. Ivan CasselmanChief Psychedelics OfficerN/AN/AN/A
Mr. Alexzander SamuelssonChief Research OfficerN/AN/AN/A
Mr. Paul MoreControllerN/AN/AN/A
Amounts are as of December 31, 2021 and compensation values are for the last fiscal year ending on that date. Pay is salary, bonuses, etc. Exercised is the value of options exercised during the fiscal year. Currency in USD.

Description

HAVN Life Sciences Inc., a biotechnology company, engages in the research and development of psychopharmacological products from plants and fungi. The Company also focuses on developing methodologies for the standardize and quality-controlled extraction of psychoactive compounds from plants and fungi, including Psilocybe spp. mushrooms; and the genera directive compounds, such as psilocybin, psilocin, and baeocystin, as well as the development of natural health care products from non-regulated compounds. The company was incorporated in 2020 and is headquartered in Richmond, Canada.

Corporate Governance

HAVN Life Sciences Inc.’s ISS Governance QualityScore as of N/A is N/A. The pillar scores are Audit: N/A; Board: N/A; Shareholder Rights: N/A; Compensation: N/A.

Corporate governance scores courtesy of Institutional Shareholder Services (ISS). Scores indicate decile rank relative to index or region. A decile score of 1 indicates lower governance risk, while a 10 indicates higher governance risk.